AesculaTech believes in building better lives through smart chemistry. We design custom smart materials for a range of biomedical, commercial, and industrial applications.
AesculaTech is a Y Combinator company in the Winter 2018 batch. Its directory entry describes it as: Responsive materials, better lives. The founder listed is Niki Bayat (Founder/CEO) (Y Combinator directory entry, November 3, 2017).
Sell to companies like AesculaTech? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2017-11-03 · the record
Pitching, partnering or investing alongside them? See who really runs and owns AesculaTech.
Free to see. No signup.
More on AesculaTech and the records around it.
Same batch, Healthcare first.
Get an email when AesculaTech changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when AesculaTech raises, hires or launches. No email unless you switch it on.
Watch AesculaTech →Get the full cited report on AesculaTech
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on AesculaTech: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
AesculaTech believes in building better lives through smart chemistry. We design custom smart materials for a range of biomedical, commercial, and industrial applications. Our platform technology, AesculaGel offers adaptive response to a wide range of stimuli and can be tailor-made for biocompatibility, material strength, and a range of other attributes. Founded by one of MIT's 35 under 35 Innovators, AesculaTech is the shared vision of scientists, engineers, and medical experts. Our cornerstone product, Humidifeye, is an ophthalmic platform to treat dry eye disease. Dry eye affects more than 25 million Americans and the global treatment market is projected higher than $6 Billion within the next decade. Our thermally responsive, form-fitting materials are suitable for sustained yet reversible occlusion across a range of treatment times. In contrast to existing technologies, our product will not extrude, or cause discomfort as it adapts to patients. Though Humidifeye is not yet FDA approved, expect to hear about it soon! In coordination with partners across several sectors, we have a variety of groundbreaking technologies in the works that live up to our vision. This work has already been recognized. AesculaTech was named a Rosenman Innovator, received a National Science Foundation I-Corps grant, was a finalist in the 2019 Octane High Tech Awards, and is a graduate of both the Y Combinator and TMCx accelerator programs. In short, Y-Combinator was only the beginning.
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on AesculaTech: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on AesculaTech covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist AesculaTechYou get an alert in MentionFox the next time this company shows up.
If you're behind AesculaTech: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for AesculaTech. With no account yet, you sign up free and land on the result.
Medical device and diagnostics startups Manufacturing and industrial startups
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-aesculatech